The 2017 ASCP Annual Meeting is in Miami Beach, FL from May 29 - June 2, 2017. The meeting will include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry that discussed key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Marlene Freeman and John Newcomer with representation of the sectors that are part of the ASCP community lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2017 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Alan Gelenberg are responsible for review of all program submissions.

We look forward to see you in Miami Beach!